Search This Blog

Thursday, July 27, 2023

Belite Starts Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for Geographic Atrophy

 

  • Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in subjects with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD)

  • There are no approved oral or non-invasive treatments for GA

  • Enrollment of approximately 430 GA subjects across multiple centers globally

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.